Search Results
Active Surveillance in 2021 Part 2: Imaging and Biomarkers
Active Surveillance 2021 - From Bench to Bedside
Active Surveillance Criteria and Follow-up Protocol
Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active Surveillance
Biomarkers’ Integration with Clinical Parameters, Imaging, and Prognostic Instruments
Active Surveillance 2022: Who Qualifies, Who Does Not and How Should it be Monitored
Active Surveillance Who is the Right Patient and What is the Right Protocol
Active Surveillance 2021 (Part 3) - Patient Selection, Monitoring, and Innocuous Interventions
Active Surveillance Results and Implications of Prospective Studies
Active Surveillance in 2022 | Laurence Klotz, MD | PCRI
Active Surveillance or: Shrinking the Gray Zone
Active Surveillance in Favorable Intermediate-Risk Prostate Cancer
